O’Melveny represented China International Capital Corporation Hong Kong Securities Limited as the sole sponsor and overall coordinator in the IPO. Qyuns Therapeutics Co., Ltd. (2509.HK) announced...
Qyuns Therapeutics’ US$31 Million Initial Public Offering
Folangsi’s HK$155 Million Hong Kong IPO
O’Melveny represented FOLANGSI CO., LTD in the transaction. FOLANGSI CO., LTD (2499.HK) (“FOLANGSI”) announced its approximately HK$155 million initial public offering and listing of H shares...
Beijing UBOX Online Technology Corp.’s HK$233.7 Million Initial Public Offering
O’Melveny assisted Beijing UBOX Online Technology Corp. on the Hong Kong laws. Sidley acted as international legal counsel for the joint sponsors. Beijing UBOX Online Technology...
3D Medicines Inc.’s Listing on the Stock Exchange of Hong Kong
Herbert Smith Freehills advised CICC and CSCI on the deal while O’Melveny recently represented 3D Medicines. CICC and CSCI acted as joint sponsors of 3D Medicines...
Rainmed Medical’s HK$146 Million IPO and Listing on the Hong Kong Stock Exchange
O’Melveny and Grandall represented Rainmed Medical Limited (2297.HK) on the deal. Herbert Smith Freehills has advised Huatai Financial Holdings. Rainmed Medical Limited (2297.HK) announced its US$19...